{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:12:26Z","timestamp":1790921546159,"version":"4.1.0"},"reference-count":19,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1183\/23120541.00725-2023","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T15:40:17Z","timestamp":1706283617000},"page":"00725-2023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583"],"prefix":"10.1183","volume":"10","author":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Badorrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"K\u00f6gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kreideweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-6186","authenticated-orcid":false,"given":"Jens M.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"2024101712164328000_10.2.00725-2023.1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"2024101712164328000_10.2.00725-2023.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201303-0411CI"},{"key":"2024101712164328000_10.2.00725-2023.3","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.3390\/ijms22115996","article-title":"Protease-antiprotease imbalance in bronchiectasis","volume":"22","author":"Oriano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024101712164328000_10.2.00725-2023.4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200213462"},{"key":"2024101712164328000_10.2.00725-2023.5","unstructured":"ClinicalTrials.gov. A study to test whether different doses of BI 1291583 help people with bronchiectasis. 2022. Date last updated: 25 January 2023. Date last accessed: 5 July 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05238675"},{"key":"2024101712164328000_10.2.00725-2023.6","doi-asserted-by":"crossref","first-page":"00633-02022","DOI":"10.1183\/23120541.00633-2022","article-title":"A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis (Airleaf\u2122)","volume":"9","author":"Chalmers","year":"2023","journal-title":"ERJ Open Res"},{"key":"2024101712164328000_10.2.00725-2023.7","unstructured":"ClinicalTrials.gov . This study tests how different doses of BI 1291583 are taken up in the body and how well they are tolerated. 2018. Date last updated: 11 October 2020. Date last accessed: 2 February 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03414008?term=NCT03414008&draw=2&rank=1"},{"key":"2024101712164328000_10.2.00725-2023.8","unstructured":"ClinicalTrials.gov . A study in healthy men and women to find out how well different doses of BI 1291583 are tolerated. 2019. Date last updated: 23 November 2021. Date last accessed: 2 February 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03868540?term=NCT03868540&draw=2&rank=1"},{"key":"2024101712164328000_10.2.00725-2023.9","unstructured":"ClinicalTrials.gov . A trial in healthy men and women to find out how well different doses of BI 1291583 are tolerated. 2021. Date last updated: 7 December 2021. Date last accessed: 2 February 2023. https:\/\/clinicaltrials.gov\/study\/NCT04866160"},{"key":"2024101712164328000_10.2.00725-2023.10","unstructured":"ClinicalTrials.gov . A study to test how food influences the amount of BI 1291583 in the blood of healthy men. 2019. Date last updated: 5 November 2023. Date last accessed: 2 February 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03837964?term=NCT03837964&draw=2&rank=1"},{"key":"2024101712164328000_10.2.00725-2023.11","unstructured":"ClinicalTrials.gov . A study in healthy men to test how itraconazole influences the amount of BI 1291583 in the blood. 2019. Date last updated: 11 November 2023. Date last accessed: 2 February 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03890887?term=NCT03890887&draw=2&rank=1"},{"key":"2024101712164328000_10.2.00725-2023.12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2009.03.016","article-title":"Papillon-Lefevre syndrome: clinical presentation and a brief review","volume":"108","author":"Dhanrajani","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2024101712164328000_10.2.00725-2023.13","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","article-title":"Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986)","volume":"59","author":"Doyle","year":"2016","journal-title":"J Med Chem"},{"key":"2024101712164328000_10.2.00725-2023.14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cpt.1053","article-title":"Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects","volume":"104","author":"Palmer","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2024101712164328000_10.2.00725-2023.15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101712164328000_10.2.00725-2023.16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Respir Res"},{"key":"2024101712164328000_10.2.00725-2023.17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40262-022-01147-w","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of the dipeptidyl peptidase 1 inhibitor brensocatib for non-cystic fibrosis bronchiectasis","volume":"61","author":"Chalmers","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2024101712164328000_10.2.00725-2023.18","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1111\/bcp.13398","article-title":"Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)","volume":"83","author":"Miller","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2024101712164328000_10.2.00725-2023.19","doi-asserted-by":"publisher","DOI":"10.1038\/70472"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00725-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:32:51Z","timestamp":1740375171000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00725-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3,25]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1183\/23120541.00725-2023"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00725-2023","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}